Susan E. Walgrave, MD, David Kist, HTL, Peter M.H. Cham, MD, and Brian D. Zelickson, MD, Minneapolis, MN
This study investigated the safety and efficacy of the confluent 2,790 nm Erbium:YSGG (PearlTM, Cutera) laser for facial rejuvenation. The 2,790 nm Er:YSGG wavelength has a lower water absorption coefficient than the 2,940 nm Er:YAG wavelength, allowing for minimally ablative resurfacing and coagulation, which may increase clinical efficacy while reducing patient downtime.
Eleven subjects (mean age 50, skin types I–III) with mild to moderate photodamage and wrinkles had two facial treatments with the 2,790 nm Er:YSGG laser using a fluence level of 3.5 J/cm2 and pulse duration of 0.4 ms, with 20% overlap. Treatments were performed 6 weeks apart. Pre–auricular biopsies from five subjects were evaluated at baseline and 6 weeks after the final treatment. Data from blinded physician photo evaluations (quartile scale of improvement) and subjects’ self–assessment of improvement (none, mild, significant, dramatic) were analyzed.
Histologically, 80% of subjects had new collagen formation in the dermal grenz zone. Increased epidermal thickness was also seen in 60% of subjects. Based on the blinded photo evaluations, 89% of subjects showed visible improvement in dyschromia, tone/texture, and fine lines. Similarly, 55% displayed visible improvement in wrinkles. Evaluators were substantially consistent (agreement between evaluators, kappa of 0.71) and accurate (agreement between evaluators versus gold standard, kappa of 0.78) about their identification of before and after photos. Subjects’ self–assessment indicated “significant” to “dramatic” improvement in dyschromia (91%), tone/texture (82%), and fine lines (64%). No serious adverse events were reported. Moderate treatment discomfort was noted with a mean pain score of 5.5 on a 10–point scale.
The minimally ablative resurfacing treatments with the 2,790 nm Er:YSGG laser demonstrated good tolerability with minimal downtime. Blinded physician evaluations indicated visible improvement in the majority of subjects with strong agreement between evaluators. Subjects were highly satisfied with their clinical improvement, especially with respect to dyschromia and tone/texture.
View the recent published works by Dr. Zelickson featured on PubMed – a service of the U.S. National Library of Medicine.